Generating a better understanding of how our medicines work in the real world ultimately allows us to benefit the patients that we serve. As a pioneer in real-world evidence (RWE) in diabetes, Sanofi has been building a large set of real world data for its insulins. Data of this kind helps demonstrate the value that our medicines bring to physicians and patients. Importantly, our RWE program helps evaluate the true effect of basal insulins on severe hypoglycemia. Sanofi has taken an innovative approach to generating this type of evidence, with the use of advanced statistical techniques and big data.